Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene therapy could lead to cure for genetic blindness:

This article was originally published in Clinica

Executive Summary

Gene therapy can improve the sight of patients with Leber's congenital amaurosis (LCA), a rare genetic eye disease that causes blindness, a study has shown. Researchers from the UCL Institute of Ophthalmology and Moorfields Eye Hospital, both in London, UK, delivered healthy copies of a gene that malfunctions in the disorder - RPE65 - into the patient's eyes using a harmless virus. One of the three patients in the trial had significantly improved night vision after the gene therapy, and no side-effects were seen. The team has already begun to trial the technique in younger patients, where they hope to achieve even better results. There are currently no effective treatments for LCA. The findings will appear in the May 22 issue of the New England Journal of Medicine.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel